Skip to main content
. 2015 Dec 18;30(3):463–472. doi: 10.1038/eye.2015.259

Table 4B. Complications of treatment.

  Bevacizumab group (n=64) Non-bevacizumab group (n=99) P-valuea
Retinal detachment 2 (3%) 0 0.15
Cataract 0 3 (3%) 0.28
Hyphema 19 (30%) 8 (8%) <0.001
Tube erosion 0 1 (1%) 1.00

Data are presented as number (percentage).

a

Two-sample Wilcoxon test.